Investment Thesis:
Strategic Pivot Success: The shift towards high-margin Finished Dosages (FD) is driving strong gross margin expansion (up nearly 600 bps YoY in Q1 FY26), offsetting legacy segment volatility.
High-Growth Entry: The acquisition of Swiss CDMO Senn Chemicals provides immediate entry into the rapidly expanding Peptide Therapeutics segment, including GLP-1 receptor agonists (anti-obesity/diabetic drugs).
Capacity & Regulatory Tailwinds: Successful US FDA clearance for the new Genome Valley facility adds 10 billion doses of capacity, positioning the company for a sustainable increase in FD sales volumes.
Attractive Valuation: The stock trades at a TTM P/E of 28.23x, which is below the Industry P/E of 34.29x, offering a favorable entry point for a company undergoing a structural transformation.
Long-Term Diversification: The new CDMO platform and focus on niche R&D areas like Oncology and ADHD ensure a pipeline of high-value products, de-risking the business model from reliance on generic bulk APIs.
For reading the complete report you can subscribe to the service by clicking this link https://www.signalz.in/subscriptions/trendflip-alpha-18500
About Subscription
Bullish Setup Based on Momentum & Fundamentals.
The stock presents a compelling buy opportunity, supported by a convergence of technical momentum and fundamental strength—a dual confirmation that often precedes sustained upside.
Momentum Indicators Signal Accumulation
a. Price Action: The stock is consistently making higher highs and higher lows, indicating a strong uptrend.
b. Volume Profile: Rising volumes on up days suggest institutional accumulation rather than speculative froth.
c. Relative Strength Index (RSI): Hovering in the 60–70 range, showing bullish momentum without being overbought.
Fundamentals Reflect Progressive Business Trajectory
d. Revenue & Margin Expansion: Consistent top-line growth accompanied by improving operating margins signals scalability.
e. Earnings Visibility: Strong quarterly results with upward revisions in EPS guidance by analysts.
f. Sector Tailwinds: Operating in a segment benefiting from macro trends (e.g., digitization, capex cycle, consumption rebound).
g. Management Commentary: Confident tone in investor calls, with clear strategic roadmap and execution track record.
Strategic Takeaway – This setup—where technicals validate timing and fundamentals justify conviction—makes the stock a candidate for both momentum-based entries and core portfolio allocation. Traders/ Investors can ride the trend with tight trailing stops